Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986403 in Relapsed/Refractory CLL or SLL
NCT05244070Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ROR1 CAR-T cells in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events (AEs) up to 2 years, Number of participants with serious adverse events (SAEs) up to 2 years and 4 more. Started Sep 2022; status: terminated.
02
Drugs
ROR1 CAR-T cells
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05244070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244070.